Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Dose-finding study of a once-daily indinavir/ritonavir regimen

Article Abstract:

Researchers determined the best combination dosage of the protease inhibitors indinavir and ritonavir so they could be taken once a day rather than two or three times a day. This is possible because ritonavir slows the metabolism of indinavir, making it last longer in the body.

Author: Lange, Joep M.A., Hugen, patricia W.H., Burger, David M., Hofstede, Hadewych J.M. ter, Koopmans, Peter P., Stek, Michael, Hekster, Yechiel A., Reiss, Peter
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2000

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy

Article Abstract:

Taking indinavir in combination with ritonavir twice a day appears to be as effective as taking indinavir alone three times a day. Ritonavir makes indinavir last longer in the body, allowing patients to reduce the risk of side effects.

Author: Lange, Joep M.A., Burger, David M., Reiss, Peter, Prins, Jan M., Hugen, Patricia W.H., Aarnoutse, Rob E., Dieleman, Jeanne P., Poll, Tom van der, Veen, Jacob H. ten, Mulder, Jan W., Meenhorst, Pieter L., Blok, Willem L., Meer, Jan T.M. van der
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2001
Evaluation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients

Article Abstract:

A study is conducted to assess the interactions between the drugs, namely tenofovir disoproxil fumarate (TDF) and the two nonnucleoside reverse inhibitors, nevirapine and efavirenz, which are used in the treatment of HIV-infected patients. The data obtained from the study demonstrates that these drugs, which can be co-administered without any need for dose adjustments, do not affect the plasma levels of the inhibitors.

Author: Burger, David M., Hekster, Yechiel A., Kearney, Brian P., Droste, Jacqueline A.H.
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2006
Science & research, Care and treatment, Research, HIV patients, Tenofovir, Reverse transcriptase inhibitors

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Ritonavir, HIV infection, Drug therapy, HIV infections, Indinavir, Dosage and administration
Similar abstracts:
  • Abstracts: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. Inhaled zanamivir for the prevention of influenza in families
  • Abstracts: A study of the relationship between placenta growth factor and gestational age, parturition, rupture of membranes, and intrauterine infection
  • Abstracts: Assessment of fetal lung volumes and liver herniation with magnetic resonance imaging in congenital diaphragmatic hernia
  • Abstracts: Histologic inflammation in the maternal and fetal compartments in a rabbit model of acute intra-amniotic infection
  • Abstracts: Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.